Alkem MedTech Private Limited, a wholly-owned subsidiary of Alkem Laboratories Limited, has announced a binding offer to acquire up to 55% stake in Swiss medical device company Occlutech Holding AG, marking the pharmaceutical company's strategic entry into the cardiovascular devices segment.

Acquisition Details

Through a binding offer executed on February 13, 2026, Alkem MedTech has proposed to acquire up to 55% of Occlutech Holding AG's equity share capital. The updated transaction parameters reflect the strategic importance of this acquisition:

Target Company Profile and Performance

Occlutech Holding AG, incorporated on December 12, 2000, is a Swiss medical device company specializing in minimally invasive cardiac implants for congenital heart defects, stroke prevention, and heart failure. The company holds the position as Europe's second-largest player in minimally invasive cardiac implants and third-largest globally.

Financial Performance Trajectory

Occlutech's financial performance demonstrates consistent growth with recent revenue expansion:

The company recorded EUR 49.40 million in revenue for calendar year 2025, representing a 15.7% compound annual growth rate over three years. Occlutech derives approximately 85% of its revenue from Europe and the United States.

Strategic Rationale and Market Position

The acquisition enables Alkem MedTech's entry into advanced cardiovascular devices, leveraging Occlutech's established global presence across over 80 countries. The target company operates manufacturing and R&D facilities in Germany and Turkey, with a global distribution hub in Sweden and clinical operations in the United States.

Executive Chairman B.N. Singh of Alkem Laboratories stated that the acquisition reinforces the company's long-term vision of becoming a global medical devices player. Kaustav Banerjee, CEO of Alkem MedTech, highlighted Occlutech's established capabilities and strong foundation for sustainable growth in high-barrier, high-value markets.

Regulatory Framework and Timeline

The transaction requires statutory approvals including foreign direct investment clearances in Italy and Sweden, with precautionary filing in France. The acquisition remains subject to definitive agreements, fulfillment of conditions precedent, and regulatory authorizations. Boston Consulting Group acted as advisor for this transaction, with completion expected by June 2026 following regulatory approvals.

Alkem Laboratories has announced its Q3FY26 financial results, delivering robust performance with 11% revenue growth and declaring an interim dividend of ₹43 per share. The pharmaceutical company also revealed a strategic acquisition in the medical devices sector through its subsidiary Alkem MedTech.

Q3FY26 Financial Performance

The company delivered strong financial metrics across key parameters for the quarter ended December 31, 2025:

R&D expenses for the quarter stood at ₹1,390 million, representing 3.7% of total revenue from operations compared to 3.9% in Q3FY25.

Business Segment Performance

Alkem's diversified revenue streams showed varied growth patterns across geographies:

According to IQVIA data, the company registered 9.8% growth compared to the Indian Pharmaceutical Market growth of 10.9%. Alkem outperformed in the acute segment by 80 basis points and marginally outperformed in chronic category by 18 basis points.

Strategic Acquisition Announcement

Alkem announced the execution of a binding term sheet to acquire a majority stake in Occlutech Holding AG, a Switzerland-based global medical devices company specializing in minimally invasive cardiac implants. The acquisition will be made through Alkem's wholly-owned subsidiary Alkem MedTech.

Sandeep Singh, Managing Director, commented: "This acquisition holds strategic importance as we work towards establishing a global footprint in medical devices. Occlutech is the third-largest player globally in the minimally invasive cardiac implants segment."

Interim Dividend Declaration

The Board of Directors declared an interim dividend of ₹43 per equity share for financial year 2025-2026:

Exceptional Items Impact

The company reported exceptional items of ₹528 million for the quarter, primarily related to the Government of India's notification of four Labour Codes effective from November 21, 2025. This represents a preliminary assessment of the incremental impact based on available information.

Management Commentary

Dr. Vikas Gupta, CEO, expressed optimism about future prospects: "Looking ahead, the planned launch of our GLP-1 semaglutide in March 2026 is expected to be among our key growth drivers. Our focus remains on execution, strengthening our product portfolio, and building long-term competitiveness across markets."